Tags

Type your tag names separated by a space and hit enter

Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients.
Psychiatry Clin Neurosci. 2004 Aug; 58(4):427-33.PC

Abstract

The efficacy of paroxetine in the treatment of obsessive-compulsive disorder in Western populations is well established. The present study compares the efficacy and safety of paroxetine with placebo in the treatment of obsessive-compulsive disorder in Japanese patients. Patients aged 16 years or older who met Diagnostic and Statistical Manual of Mental Disorders (4th edn; DSM-IV) criteria for obsessive-compulsive disorder and had a Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score of >/=16 were randomized to receive 12 weeks' therapy in a double-blind manner. Paroxetine 20-50 mg/day or placebo was administered following a 1 week, placebo run-in phase. One hundred and ninety-one patients were randomized to either paroxetine or placebo, 188 patients were assessed as the full analysis set (FAS) and 144 patients completed the 12 week study. After adjustment for the Y-BOCS total score at baseline, reductions in obsessive-compulsive total score at week 6 and at the end of therapy were significantly greater in the paroxetine group than the placebo group. Most of the adverse events that occurred during the study were of mild to moderate intensity. Paroxetine is effective and well tolerated in Japanese adult patients with obsessive-compulsive disorder.

Authors+Show Affiliations

Showa University School of Medicine, Tokyo, Japan. kamijima@med.showa-u.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

15298657

Citation

Kamijima, Kunitoshi, et al. "Paroxetine in the Treatment of Obsessive-compulsive Disorder: Randomized, Double-blind, Placebo-controlled Study in Japanese Patients." Psychiatry and Clinical Neurosciences, vol. 58, no. 4, 2004, pp. 427-33.
Kamijima K, Murasaki M, Asai M, et al. Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients. Psychiatry Clin Neurosci. 2004;58(4):427-33.
Kamijima, K., Murasaki, M., Asai, M., Higuchi, T., Nakajima, T., Taga, C., & Matsunaga, H. (2004). Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients. Psychiatry and Clinical Neurosciences, 58(4), 427-33.
Kamijima K, et al. Paroxetine in the Treatment of Obsessive-compulsive Disorder: Randomized, Double-blind, Placebo-controlled Study in Japanese Patients. Psychiatry Clin Neurosci. 2004;58(4):427-33. PubMed PMID: 15298657.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients. AU - Kamijima,Kunitoshi, AU - Murasaki,Mitsukuni, AU - Asai,Masahiro, AU - Higuchi,Teruhiko, AU - Nakajima,Teruo, AU - Taga,Chiaki, AU - Matsunaga,Hisato, PY - 2004/8/10/pubmed PY - 2004/12/16/medline PY - 2004/8/10/entrez SP - 427 EP - 33 JF - Psychiatry and clinical neurosciences JO - Psychiatry Clin Neurosci VL - 58 IS - 4 N2 - The efficacy of paroxetine in the treatment of obsessive-compulsive disorder in Western populations is well established. The present study compares the efficacy and safety of paroxetine with placebo in the treatment of obsessive-compulsive disorder in Japanese patients. Patients aged 16 years or older who met Diagnostic and Statistical Manual of Mental Disorders (4th edn; DSM-IV) criteria for obsessive-compulsive disorder and had a Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score of >/=16 were randomized to receive 12 weeks' therapy in a double-blind manner. Paroxetine 20-50 mg/day or placebo was administered following a 1 week, placebo run-in phase. One hundred and ninety-one patients were randomized to either paroxetine or placebo, 188 patients were assessed as the full analysis set (FAS) and 144 patients completed the 12 week study. After adjustment for the Y-BOCS total score at baseline, reductions in obsessive-compulsive total score at week 6 and at the end of therapy were significantly greater in the paroxetine group than the placebo group. Most of the adverse events that occurred during the study were of mild to moderate intensity. Paroxetine is effective and well tolerated in Japanese adult patients with obsessive-compulsive disorder. SN - 1323-1316 UR - https://www.unboundmedicine.com/medline/citation/15298657/Paroxetine_in_the_treatment_of_obsessive_compulsive_disorder:_randomized_double_blind_placebo_controlled_study_in_Japanese_patients_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1323-1316&date=2004&volume=58&issue=4&spage=427 DB - PRIME DP - Unbound Medicine ER -